FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801421710> ?p ?o ?g. }

• W2801421710 endingPage "1567" @default.
• W2801421710 startingPage "1556" @default.
• W2801421710 abstract "To determine whether emixustat hydrochloride (emixustat) reduces the rate of enlargement of geographic atrophy (GA) compared with placebo in subjects with age-related macular degeneration (AMD) and to evaluate the safety and tolerability of emixustat over 24 months of treatment.Multicenter, randomized, double-masked, placebo-controlled, phase 2b/3 clinical trial.Patients with GA secondary to AMD, a visual acuity score of at least 35 letters, and GA with a total area of 1.25 to 18 mm2 were enrolled.Subjects were randomized (1:1:1:1) to emixustat 2.5 mg, 5 mg, 10 mg, or placebo, administered orally once daily for 24 months. Visits included screening, baseline, and months 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, and 25.The primary efficacy end point was the mean annual growth rate of total GA area in the study eye, as measured by a central reading center using fundus autofluorescence (FAF) images. The change from baseline in normal luminance best-corrected visual acuity (NL-BCVA) was a secondary efficacy end point.Of 508 randomized subjects, 320 completed the study. Demographics and baseline characteristics were comparable between treatment groups. On average, GA lesions in the study eye grew at a similar rate in each group (emixustat: 1.69 to 1.84 mm2/year; placebo: 1.69 mm2/year; P ≥ 0.81). Changes in NL-BCVA were also comparable between groups. Subjects with a larger low luminance deficit (LLD) at baseline (≥20 letters) demonstrated a more rapid growth of GA over 24 months. No relationship was observed between the risk-allele status of the AMD-associated single-nucleotide polymorphisms tested and the growth rate of GA. The most common adverse events in emixustat-treated subjects were delayed dark adaptation (55%), chromatopsia (18%), visual impairment (15%), and erythropsia (15%).Emixustat did not reduce the growth rate of GA in AMD. The most common adverse events were ocular in nature and likely related to the drug's mechanism of action. Data gained from this study over a 2-year period add to the understanding of the natural history of GA and the baseline characteristics affecting the growth rate of GA." @default.
• W2801421710 created "2018-05-17" @default.
• W2801421710 creator A5016922490 @default.
• W2801421710 creator A5026181496 @default.
• W2801421710 creator A5028848967 @default.
• W2801421710 creator A5038443879 @default.
• W2801421710 creator A5045002617 @default.
• W2801421710 creator A5047852117 @default.
• W2801421710 creator A5078619902 @default.
• W2801421710 creator A5083062288 @default.
• W2801421710 creator A5087700840 @default.
• W2801421710 creator A5088428133 @default.
• W2801421710 date "2018-10-01" @default.
• W2801421710 modified "2023-10-15" @default.
• W2801421710 title "Emixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration" @default.
• W2801421710 cites W100965007 @default.
• W2801421710 cites W1158091699 @default.
• W2801421710 cites W1541005345 @default.
• W2801421710 cites W1580331077 @default.
• W2801421710 cites W1760506500 @default.
• W2801421710 cites W1934543195 @default.
• W2801421710 cites W1981344509 @default.
• W2801421710 cites W1981544118 @default.
• W2801421710 cites W2000774921 @default.
• W2801421710 cites W2014007498 @default.
• W2801421710 cites W2019731198 @default.
• W2801421710 cites W2021727046 @default.
• W2801421710 cites W2025911898 @default.
• W2801421710 cites W2032463068 @default.
• W2801421710 cites W2052064127 @default.
• W2801421710 cites W2054857117 @default.
• W2801421710 cites W2062535668 @default.
• W2801421710 cites W2076961896 @default.
• W2801421710 cites W2081268901 @default.
• W2801421710 cites W2082069330 @default.
• W2801421710 cites W2111379072 @default.
• W2801421710 cites W2136537767 @default.
• W2801421710 cites W2144523453 @default.
• W2801421710 cites W2339881828 @default.
• W2801421710 cites W2341659916 @default.
• W2801421710 cites W2401288801 @default.
• W2801421710 cites W2545082692 @default.
• W2801421710 cites W2558641953 @default.
• W2801421710 cites W2565136318 @default.
• W2801421710 cites W2672043438 @default.
• W2801421710 cites W267801964 @default.
• W2801421710 cites W2735396028 @default.
• W2801421710 cites W2739036282 @default.
• W2801421710 cites W2765808721 @default.
• W2801421710 cites W62535517 @default.
• W2801421710 doi "https://doi.org/10.1016/j.ophtha.2018.03.059" @default.
• W2801421710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29716784" @default.
• W2801421710 hasPublicationYear "2018" @default.
• W2801421710 type Work @default.
• W2801421710 sameAs 2801421710 @default.
• W2801421710 citedByCount "95" @default.
• W2801421710 countsByYear W28014217102018 @default.
• W2801421710 countsByYear W28014217102019 @default.
• W2801421710 countsByYear W28014217102020 @default.
• W2801421710 countsByYear W28014217102021 @default.
• W2801421710 countsByYear W28014217102022 @default.
• W2801421710 countsByYear W28014217102023 @default.
• W2801421710 crossrefType "journal-article" @default.
• W2801421710 hasAuthorship W2801421710A5016922490 @default.
• W2801421710 hasAuthorship W2801421710A5026181496 @default.
• W2801421710 hasAuthorship W2801421710A5028848967 @default.
• W2801421710 hasAuthorship W2801421710A5038443879 @default.
• W2801421710 hasAuthorship W2801421710A5045002617 @default.
• W2801421710 hasAuthorship W2801421710A5047852117 @default.
• W2801421710 hasAuthorship W2801421710A5078619902 @default.
• W2801421710 hasAuthorship W2801421710A5083062288 @default.
• W2801421710 hasAuthorship W2801421710A5087700840 @default.
• W2801421710 hasAuthorship W2801421710A5088428133 @default.
• W2801421710 hasBestOaLocation W28014217101 @default.
• W2801421710 hasConcept C118487528 @default.
• W2801421710 hasConcept C126322002 @default.
• W2801421710 hasConcept C141071460 @default.
• W2801421710 hasConcept C142724271 @default.
• W2801421710 hasConcept C168563851 @default.
• W2801421710 hasConcept C197934379 @default.
• W2801421710 hasConcept C203092338 @default.
• W2801421710 hasConcept C204787440 @default.
• W2801421710 hasConcept C27081682 @default.
• W2801421710 hasConcept C2776403814 @default.
• W2801421710 hasConcept C2778257484 @default.
• W2801421710 hasConcept C2778375690 @default.
• W2801421710 hasConcept C2991880128 @default.
• W2801421710 hasConcept C71924100 @default.
• W2801421710 hasConceptScore W2801421710C118487528 @default.
• W2801421710 hasConceptScore W2801421710C126322002 @default.
• W2801421710 hasConceptScore W2801421710C141071460 @default.
• W2801421710 hasConceptScore W2801421710C142724271 @default.
• W2801421710 hasConceptScore W2801421710C168563851 @default.
• W2801421710 hasConceptScore W2801421710C197934379 @default.
• W2801421710 hasConceptScore W2801421710C203092338 @default.
• W2801421710 hasConceptScore W2801421710C204787440 @default.
• W2801421710 hasConceptScore W2801421710C27081682 @default.
• W2801421710 hasConceptScore W2801421710C2776403814 @default.

• next